Sex differences in the prevalence and clinical correlates of hyperhomocysteinemia in patients with bipolar disorder. (13th February 2020)

• Record Type: Journal Article
• Authors: Mu, Li; Lin, Yezhe; Huang, Xingbing; Ning, Yuping; Wu, Fengchun; Zhang, Xiang Yang
• Is Part Of: Human psychopharmacology. Volume 35:Number 2(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-02-13
• Subjects: bipolar disorder -- homocysteine -- overweight -- sex difference -- valproate; Psychopharmacology -- Periodicals; Psychotropic drugs -- Periodicals; Psychopharmacology -- Periodicals; Psychotropic Drugs -- pharmacology -- Periodicals; 615.78
• DOI: 10.1002/hup.2724
• Languages: English
• ISSNs: 0885-6222

Abstract

Abstract: Objective: Sex differences in bipolar disorder are well recognized but little attention has been paid to sex differences in homocysteine or hyperhomocysteinemia in bipolar patients. This study compared gender differences in homocysteine levels and rates of hyperhomocysteinemia in Chinese inpatients with bipolar disorder. Methods: A total of 198 BD patients and 84 healthy controls were enrolled. The Young Mania Rating Scale, Hamilton Depression Rating Scale, and the Clinical Global Impressions–Severity scale were used to assess the affective symptomatology. Fasting plasma Hcy levels were measured by high‐performance liquid chromatography. Results: Men had higher homocysteine levels than women and the prevalence of hyperhomocysteinemia in male patients was approximately twice that in female patients. Logistic regression analyses showed that HHcy was associated with less frequent use of valproate in males and being overweight in females. Further correlation analysis and multivariate regression analysis demonstrated that Hcy levels were inversely correlated with valproate treatment in men and positively associated with overweight in women. Conclusions: In bipolar patients, there are significant differences between sexes in the levels of homocysteine and prevalence of hyperhomocysteinemia. This appears to be associated with lower prevalence of valproate prescribing in men and with being overweight in women.